Imunon, Inc. (identified in this filing as Celsion Corporation) — Form 10-Q summary
Reporting period: Three and nine months ended September 30, 2013. The filing is signed November 12, 2013. The company describes itself as a clinical-stage oncology drug developer focused on heat-activated liposomal therapies; its lead candidate is ThermoDox.
Financial performance and position
| Metric | Q3 2013 | Q3 2012 | Nine months 2013 | Nine months 2012 |
|---|---|---|---|---|
| Licensing revenue | $125,000 | $0 | $375,000 | $0 |
| Research and development expense | $2.27 million | $3.54 million | $7.49 million | $12.34 million |
| General and administrative expense | $1.39 million | $1.42 million | $5.03 million | $4.59 million |
| Operating loss | $3.53 million | $4.96 million | $12.15 million | $16.93 million |
| Net loss | $4.07 million | $6.02 million | $4.30 million | $18.31 million |
| Net loss attributable to common shareholders | $4.07 million | $6.02 million | $8.90 million | $18.31 million |
The nine-month 2013 net loss includes an $8.14 million non-cash gain from revaluing warrant liabilities; common-shareholder loss also includes a $4.60 million non-cash deemed dividend related to preferred stock. These items materially affect period comparisons. Per-share losses were reported as $0.30 for Q3 2013 and $0.76 for the first nine months of 2013, retroactively adjusted for the subsequent 1-for-4.5 reverse split.
- Cash flow: Operating activities used $6.36 million in the first nine months of 2013, versus $16.17 million in 2012. Investing activities used $24.37 million, principally reflecting net purchases of investment securities. Financing activities provided $28.91 million, principally from equity and preferred-stock offerings.
- Liquidity: At September 30, 2013, cash and cash equivalents were $13.17 million and available-for-sale investments were $32.04 million; including accrued investment interest, management reported $45.5 million in cash and short-term investments. Working capital was $40.0 million, up from $18.6 million at December 31, 2012.
- Debt and liabilities: Notes payable totaled $4.29 million, including $1.94 million current and $2.35 million non-current; the secured term loan bears 11.75% interest and matures October 15, 2015. The company said it was in compliance with loan covenants. Total liabilities were $18.29 million.
- Margins: The company had no meaningful product-sales base from which to assess product margins; the filing reports licensing revenue and operating losses.
Material changes and unusual items
- ThermoDox with radiofrequency ablation failed the HEAT Phase III trial’s primary endpoint, progression-free survival, in January 2013. R&D spending declined substantially, including lower HEAT trial costs; the company also deferred its ABLATE Phase II study and cut approximately one-third of its workforce in an April restructuring.
- October 2013 post-hoc analysis of HEAT data suggested possible overall-survival benefit in a subgroup receiving longer RFA treatment, but the reported result was not statistically significant (hazard ratio 0.63; 95% confidence interval 0.393–1.011; p=0.056), and median overall survival had not been reached. The filing cautions that the subgroup findings require careful interpretation.
- Hisun paid a non-refundable $5 million technology-development fee in January 2013. The company recorded it as deferred revenue and recognized $375,000 through September over the agreement’s 10-year term. A July memorandum of understanding described further collaboration and prospective non-dilutive financing, but the filing does not establish that all contemplated funding or arrangements were completed.
- The February preferred-stock financing generated approximately $13.6 million net proceeds; all preferred shares had converted by September 30. A June common-stock offering generated approximately $9.1 million net proceeds. The company also raised approximately $6.7 million net through its ATM program before pausing sales under offering-related restrictions.
- In October 2013, after quarter-end, the company effected a 1-for-4.5 reverse split. It reported 13,604,975 common shares outstanding as of November 11, 2013. The split does not itself provide new capital.
- The company disclosed an accounting error concerning a 2011 convertible preferred-stock beneficial conversion feature: 2011 interest expense and net loss had been understated by approximately $5 million. Management considered the error immaterial and said it had no effect on cash or total stockholders’ equity; it adjusted balance-sheet equity accounts and warned that the SEC could disagree and require restatement.
Outlook, risks, and contingencies
Management said it expected to submit a proposed pivotal Phase III protocol to the FDA in Q4 2013 and anticipated starting a global multicenter trial in the first half of 2014, subject to review and further development decisions. The company continued follow-up of HEAT patients for overall survival. It also was evaluating strategic alternatives, including partnerships, acquisitions, or a merger, without assurance of a transaction.
The company expects continued operating losses and states that substantial additional capital will be needed to advance development, manufacturing, and potential commercialization. It had no committed financing source and warned that inability to raise capital could delay, reduce, or end programs; additional equity financing could dilute shareholders. Other principal risks include clinical and regulatory failure, dependence on third-party trial operators, limited product revenue prospects, competition, intellectual-property and reimbursement risks, stock-price volatility, and possible failure to maintain Nasdaq listing requirements. No material legal proceedings were reported. Management said disclosure controls were effective at the reasonable-assurance level and reported no materially affecting change in internal controls during the period.
Important facts for investors to verify
- Confirm the correct issuer identity: the supplied request names Imunon, Inc., but this 2013 filing is for Celsion Corporation.
- Review subsequent HEAT overall-survival results, the statistical strength of the post-hoc subgroup analysis, and the status and FDA feedback for the proposed pivotal trial.
- Assess cash burn, future capital requirements, and whether Hisun’s contemplated collaboration or financing became definitive and funded.
- Check the reverse-split-adjusted share count, outstanding warrants and options, and any later equity issuance or dilution.
- Review the warrant-liability accounting and the 2011 beneficial-conversion-feature correction, including whether any restatement or further accounting action followed.